Mylicongas 50 Chewable Tablets 40 mg

WARNINGS
Do not exceed the recommended dose. The medicine contains lactose and is therefore not suitable for subjects with lactase deficiency, galactosemia or glucose / galactose malabsorption syndrome.
PHARMACOTHERAPEUTIC CATEGORY
Other drugs for intestinal functional disorders.
STORAGE
Keep the medicine in the original package to protect the product from light and humidity.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to the active substance or to any of the excipients. Generally contraindicated in pregnancy.
NAME
MYLICONGAS
EXCIPIENTS
Saccharin; alginic acid; lactose; sodium bicarbonate; povidone; hydrated calcium silicate; magnesium stearate.
SIDE EFFECTS
No undesirable effects due to the drug were highlighted.
PREGNANCY AND BREASTFEEDING
There are no adequate data on use in pregnant women, therefore it should not be used in pregnancy unless there is a real need and after a risk / benefit assessment by the physician. It is not known whether simethicone is excreted in human milk. The excretion of simethicone into breast milk has not been studied in animals. The decision whether to continue / discontinue breastfeeding or to continue / discontinue simethicone therapy should be made taking into account the benefit of breastfeeding for the infant and the benefit of simethicone therapy for the woman.
INDICATIONS
Symptomatic treatment of gastrointestinal bloating and adult aerophagia.
INTERACTIONS
No incompatibilities with other drugs are known, nor have they been reported.
DOSAGE
Adults: 4 tablets per day (2 at the end of each main meal). The tablets must be chewed.
ACTIVE PRINCIPLES
Simethicone (activated dimethylpolysiloxane) 40 mg.